These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33307969)

  • 41. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
    Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
    Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
    Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
    Leuk Res; 2018 Sep; 72():92-95. PubMed ID: 30118897
    [No Abstract]   [Full Text] [Related]  

  • 43. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
    Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
    J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mees lines and Beau lines after chemotherapy.
    Huang TC; Chao TY
    CMAJ; 2010 Feb; 182(3):E149. PubMed ID: 20008502
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
    Murphy T; Yee KWL
    Expert Opin Pharmacother; 2017 Nov; 18(16):1765-1780. PubMed ID: 29017371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
    Ali S; Dunmore HM; Karres D; Hay JL; Salmonsson T; Gisselbrecht C; Sarac SB; Bjerrum OW; Hovgaard D; Barbachano Y; Nagercoil N; Pignatti F
    Oncologist; 2019 May; 24(5):e171-e179. PubMed ID: 30898889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bilateral submandibular salivary gland enlargement during chemotherapy for acute myeloid leukaemia--beneficial effect of propranolol.
    Dabadghao S; Srivastava A; Dennison D
    Acta Haematol; 1996; 96(2):112. PubMed ID: 8701699
    [No Abstract]   [Full Text] [Related]  

  • 51. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.
    Wahlin A; Hörnsten P; Hedenus M; Malm C
    Cancer Chemother Pharmacol; 1991; 28(6):480-3. PubMed ID: 1934252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AML: New Drugs but New Challenges.
    Burnett A; Stone R
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
    Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL
    Leuk Lymphoma; 2020 May; 61(5):1188-1194. PubMed ID: 32102577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
    Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
    Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
    Hui YF; Cortes JE
    Pharmacotherapy; 2000 Oct; 20(10):1221-3. PubMed ID: 11034047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recurrent bilateral parotitis in acute myeloid leukemia.
    Shpilberg O; Ra'anani P; Ben-Bassat I; Ramot B
    Acta Haematol; 1991; 86(1):56. PubMed ID: 1950368
    [No Abstract]   [Full Text] [Related]  

  • 58. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
    Chen EC; Fathi AT; Brunner AM
    Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pruritic papules after induction chemotherapy with daunorubicin and cytarabine.
    Simmons E; Foutouhi S; Tartar DM; Kiuru M
    Dermatol Online J; 2022 Jun; 28(3):. PubMed ID: 36259808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML).
    Battipaglia G; Avilia S; Morelli E; Caranci F; Perna F; Camera A
    Ann Hematol; 2012 Aug; 91(8):1327-8. PubMed ID: 22237936
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.